title: American Society of Clinical Oncology Position Statement: Strategies for Reducing Cancer Health Disparities Among Sexual and Gender Minority Populations.
abstract: ASCO is committed to addressing the needs of sexual and gender minority (SGM) populations as a diverse group at risk for receiving disparate care and having suboptimal experiences, including discrimination, throughout the cancer care continuum. This position statement outlines five areas of recommendations to address the needs of both SGM populations affected by cancer and members of the oncology workforce who identify as SGM: (1) patient education and support; (2) workforce development and diversity; (3) quality improvement strategies; (4) policy solutions; and (5) research strategies. In making these recommendations, the Society calls for increased outreach and educational support for SGM patients; increased SGM cultural competency training for providers; improvement of quality-of-care metrics that include sexual orientation and gender information variables; and increased data collection to inform future work addressing the needs of SGM communities.
authors.affiliation: Jennifer Griggs, University of Michigan, Ann Arbor, MI; Shail Maingi, New Jersey Medical School-University Hospital Cancer Center, Newark, NJ; Victoria Blinder and Larry Norton, Memorial Sloan Kettering Cancer Center, New York, NY; Neelima Denduluri, US Oncology, The Woodlands, TX; Alok A. Khorana, Cleveland Clinic, Cleveland, OH; Michael Francisco and Dana S. Wollins, American Society of Clinical Oncology, Alexandria, VA; and Julia H. Rowland, National Cancer Institute, Bethesda, MD.
authors.forename: Jennifer
authors.initials: J
authors.lastname: Griggs
authors.affiliation: Jennifer Griggs, University of Michigan, Ann Arbor, MI; Shail Maingi, New Jersey Medical School-University Hospital Cancer Center, Newark, NJ; Victoria Blinder and Larry Norton, Memorial Sloan Kettering Cancer Center, New York, NY; Neelima Denduluri, US Oncology, The Woodlands, TX; Alok A. Khorana, Cleveland Clinic, Cleveland, OH; Michael Francisco and Dana S. Wollins, American Society of Clinical Oncology, Alexandria, VA; and Julia H. Rowland, National Cancer Institute, Bethesda, MD.
authors.forename: Shail
authors.initials: S
authors.lastname: Maingi
authors.affiliation: Jennifer Griggs, University of Michigan, Ann Arbor, MI; Shail Maingi, New Jersey Medical School-University Hospital Cancer Center, Newark, NJ; Victoria Blinder and Larry Norton, Memorial Sloan Kettering Cancer Center, New York, NY; Neelima Denduluri, US Oncology, The Woodlands, TX; Alok A. Khorana, Cleveland Clinic, Cleveland, OH; Michael Francisco and Dana S. Wollins, American Society of Clinical Oncology, Alexandria, VA; and Julia H. Rowland, National Cancer Institute, Bethesda, MD.
authors.forename: Victoria
authors.initials: V
authors.lastname: Blinder
authors.affiliation: Jennifer Griggs, University of Michigan, Ann Arbor, MI; Shail Maingi, New Jersey Medical School-University Hospital Cancer Center, Newark, NJ; Victoria Blinder and Larry Norton, Memorial Sloan Kettering Cancer Center, New York, NY; Neelima Denduluri, US Oncology, The Woodlands, TX; Alok A. Khorana, Cleveland Clinic, Cleveland, OH; Michael Francisco and Dana S. Wollins, American Society of Clinical Oncology, Alexandria, VA; and Julia H. Rowland, National Cancer Institute, Bethesda, MD.
authors.forename: Neelima
authors.initials: N
authors.lastname: Denduluri
authors.affiliation: Jennifer Griggs, University of Michigan, Ann Arbor, MI; Shail Maingi, New Jersey Medical School-University Hospital Cancer Center, Newark, NJ; Victoria Blinder and Larry Norton, Memorial Sloan Kettering Cancer Center, New York, NY; Neelima Denduluri, US Oncology, The Woodlands, TX; Alok A. Khorana, Cleveland Clinic, Cleveland, OH; Michael Francisco and Dana S. Wollins, American Society of Clinical Oncology, Alexandria, VA; and Julia H. Rowland, National Cancer Institute, Bethesda, MD.
authors.forename: Alok A
authors.initials: AA
authors.lastname: Khorana
authors.affiliation: Jennifer Griggs, University of Michigan, Ann Arbor, MI; Shail Maingi, New Jersey Medical School-University Hospital Cancer Center, Newark, NJ; Victoria Blinder and Larry Norton, Memorial Sloan Kettering Cancer Center, New York, NY; Neelima Denduluri, US Oncology, The Woodlands, TX; Alok A. Khorana, Cleveland Clinic, Cleveland, OH; Michael Francisco and Dana S. Wollins, American Society of Clinical Oncology, Alexandria, VA; and Julia H. Rowland, National Cancer Institute, Bethesda, MD.
authors.forename: Larry
authors.initials: L
authors.lastname: Norton
authors.affiliation: Jennifer Griggs, University of Michigan, Ann Arbor, MI; Shail Maingi, New Jersey Medical School-University Hospital Cancer Center, Newark, NJ; Victoria Blinder and Larry Norton, Memorial Sloan Kettering Cancer Center, New York, NY; Neelima Denduluri, US Oncology, The Woodlands, TX; Alok A. Khorana, Cleveland Clinic, Cleveland, OH; Michael Francisco and Dana S. Wollins, American Society of Clinical Oncology, Alexandria, VA; and Julia H. Rowland, National Cancer Institute, Bethesda, MD.
authors.forename: Michael
authors.initials: M
authors.lastname: Francisco
authors.affiliation: Jennifer Griggs, University of Michigan, Ann Arbor, MI; Shail Maingi, New Jersey Medical School-University Hospital Cancer Center, Newark, NJ; Victoria Blinder and Larry Norton, Memorial Sloan Kettering Cancer Center, New York, NY; Neelima Denduluri, US Oncology, The Woodlands, TX; Alok A. Khorana, Cleveland Clinic, Cleveland, OH; Michael Francisco and Dana S. Wollins, American Society of Clinical Oncology, Alexandria, VA; and Julia H. Rowland, National Cancer Institute, Bethesda, MD.
authors.forename: Dana S
authors.initials: DS
authors.lastname: Wollins
authors.affiliation: Jennifer Griggs, University of Michigan, Ann Arbor, MI; Shail Maingi, New Jersey Medical School-University Hospital Cancer Center, Newark, NJ; Victoria Blinder and Larry Norton, Memorial Sloan Kettering Cancer Center, New York, NY; Neelima Denduluri, US Oncology, The Woodlands, TX; Alok A. Khorana, Cleveland Clinic, Cleveland, OH; Michael Francisco and Dana S. Wollins, American Society of Clinical Oncology, Alexandria, VA; and Julia H. Rowland, National Cancer Institute, Bethesda, MD.
authors.forename: Julia H
authors.initials: JH
authors.lastname: Rowland
mesh_terms: D005783:Gender Identity; D054624:Health Status Disparities; D054625:Healthcare Disparities; D006801:Humans; D008495:Medical Oncology; D009369:Neoplasms / Q000628:therapy*; D000072339:Sexual and Gender Minorities; D012955:Societies, Medical; D014481:United States